Russian Journal of Child NeurologyRussian Journal of Child NeurologyРусский журнал детской неврологии2073-88032412-9178Publishing House ABV Press24610.17650/2073-8803-2018-13-1-34-41ORIGINAL REPORTSОРИГИНАЛЬНЫЕ СТАТЬИUsing of cerebrolysin in patients with epilepsyПрименение церебролизина у пациентов с эпилепсиейKotovA. S.КотовА. С.
Russian Federation

61/2 Shchepkina St., Moscow 129110

129110 Москва, ул. Щепкина, 61/2

alex-013@yandex.ruM.F. Vladimirsky Moscow Regional Research Clinical InstituteГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»1501201813134411004201810042018Copyright ©; 2018, ABV-PressCopyright ©; 2018, АБВ-пресс2018ABV-PressАБВ-прессhttps://rjdn.abvpress.ru/jour/about/editorialPolicieshttps://rjdn.abvpress.ru/jour/article/view/246

Objective: to assess the efficiency and tolerability of cerebrolysin in patients with epilepsy.

Materials and methods. Sixty six epileptic patients with low Montreal Cognitive Assessment results (less than 26 scores) were studied. The examination included neurologic examination, routine electroencephalography and/or video-electroencephalography monitoring, magnetic resonance imaging of the brain, assessment of clinical and biochemical blood tests. Criteria for exclusion were processual brain damage and noncompliance. All patients were assigned cerebrolysin 10 ml intravenous, an assessment of seizures frequency and cognitive functions was performed 1 and 3 months after the 1st visit. All the procedures of the study were performed by 38 patients out of 66.

Results. In a group of patients with Alzheimer’s dementia there was a statistically insignificant tendency to decrease the final score over time (obviously associated with the progression of the disease); in the group of patients with brain damage the results of testing were improved, presumably related to the processes of neuroplasticity induced by cerebrolysin.

Conclusion. Our results suggest that cerebrolysin is well tolerated and does not increase the frequency of epileptic seizures in patients with stable epilepsy (with no risk of developing status epilepticus) and cognitive disorders.

epilepsycerebrolysinneuroplasticityэпилепсияцеребролизиннейропластичность1. Котов А.С. Комплаентность у больных эпилепсией. Журнал неврологии и психиатрии им. С.С. Корсакова 2010;110(11):46–8. [Kotov A.S. Compliance in patients with epilepsy. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2010;110(11):46–8. (In Russ.)].Котов А.С. Комплаентность у больных эпилепсией. Журнал неврологии и психиатрии им. С.С. Корсакова 2010;110(11):46–8. [Kotov A.S. Compliance in patients with epilepsy. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2010;110(11):46–8. (In Russ.)].2. Котов А.С. Эффективность и безопасность церебролизина у пациентов с эпилепсией, имеющих когнитивные нарушения. Русский медицинский журнал 2015;(24):1–4. [Kotov A.S. Efficacy and safety of cerebrolysin in patients with epilepsy and cognitive disorders. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2015;(24):1–4. (In Russ.)].Котов А.С. Эффективность и безопасность церебролизина у пациентов с эпилепсией, имеющих когнитивные нарушения. Русский медицинский журнал 2015;(24):1–4. [Kotov A.S. Efficacy and safety of cerebrolysin in patients with epilepsy and cognitive disorders. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2015;(24):1–4. (In Russ.)].3. Котов А.С. Эффективность и безопасность церебролизина у пациентов с эпилепсией, имеющих когнитивные нарушения (продолженное исследование). Медицинский алфавит 2016;26(4):22–5. [Kotov A.S. Efficacy and safety of cerebrolysin in patients with epilepsy and cognitive disorders (longitudinal study). Meditsinskiy alfavit = Medical Alphabet 2016;26(4):22–5. (In Russ.)].Котов А.С. Эффективность и безопасность церебролизина у пациентов с эпилепсией, имеющих когнитивные нарушения (продолженное исследование). Медицинский алфавит 2016;26(4):22–5. [Kotov A.S. Efficacy and safety of cerebrolysin in patients with epilepsy and cognitive disorders (longitudinal study). Meditsinskiy alfavit = Medical Alphabet 2016;26(4):22–5. (In Russ.)].4. Котов А.С., Елисеев Ю.В., Мухина Е.В. Сосудистая деменция. Медицинский совет 2016;(5):39–41. [Kotov A.S., Eliseev Yu.V., Mukhina E.V. Vascular dementia. Meditsinskiy sovet = Medical Council 2016;(5):39–41. (In Russ.)].Котов А.С., Елисеев Ю.В., Мухина Е.В. Сосудистая деменция. Медицинский совет 2016;(5):39–41. [Kotov A.S., Eliseev Yu.V., Mukhina E.V. Vascular dementia. Meditsinskiy sovet = Medical Council 2016;(5):39–41. (In Russ.)].5. Котов А.С., Елисеев Ю.В., Семенова Е.И. Болезнь Альцгеймера: от теории к практике. Медицинский совет 2015;(18):41–5. [Kotov A.S., Eliseev Yu.V., Semenova E.I. Alzheimer’s disease: from theory to practice. Meditsinskiy sovet = Medical Council 2015;(18):41–5. (In Russ.)].Котов А.С., Елисеев Ю.В., Семенова Е.И. Болезнь Альцгеймера: от теории к практике. Медицинский совет 2015;(18):41–5. [Kotov A.S., Eliseev Yu.V., Semenova E.I. Alzheimer’s disease: from theory to practice. Meditsinskiy sovet = Medical Council 2015;(18):41–5. (In Russ.)].6. Котов А.С., Силина Е.В., Елисеев Ю.В. Когнитивные расстройства при цереброваскулярных заболеваниях. М.: МОНИКИ, 2013. 31 c. [Kotov A.S., Silina E.V., Eliseev Yu.V. Cognitive disorders in patients with cerebrovascular diseases. Moscow: MONIKI, 2013. 31 р. (In Russ.)].Котов А.С., Силина Е.В., Елисеев Ю.В. Когнитивные расстройства при цереброваскулярных заболеваниях. М.: МОНИКИ, 2013. 31 c. [Kotov A.S., Silina E.V., Eliseev Yu.V. Cognitive disorders in patients with cerebrovascular diseases. Moscow: MONIKI, 2013. 31 р. (In Russ.)].7. Hutter-Paier B., Grygar E., Frühwirth M. et al. Further evidence that cerebrolysin protects cortical neurons from neurodegeneration in vitro. J Neural Transm Suppl 1998;(53):363–72. PMID: 9700672.Hutter-Paier B., Grygar E., Frühwirth M. et al. Further evidence that cerebrolysin protects cortical neurons from neurodegeneration in vitro. J Neural Transm Suppl 1998;(53):363–72. PMID: 9700672.8. Onishchenko L.S., Gaikova O.N., Yanishevskii S.N. Changes at the focus of experimental ischemic stroke treated with neuroprotective agents. Neurosci Behav Physiol 2008;38(1):49–54. PMID: 18097760. DOI: 10.1007/s11055- 008-0007-1.Onishchenko L.S., Gaikova O.N., Yanishevskii S.N. Changes at the focus of experimental ischemic stroke treated with neuroprotective agents. Neurosci Behav Physiol 2008;38(1):49–54. PMID: 18097760. DOI: 10.1007/s11055- 008-0007-1.9. Onose G., Mureşanu D.F., Ciurea A.V. et al. Neuroprotective and consequent neurorehabilitative clinical outcomes, in patients treated with the pleiotropic drug cerebrolysin. J Med Life 2009;2(4):350–60. PMID: 20108748.Onose G., Mureşanu D.F., Ciurea A.V. et al. Neuroprotective and consequent neurorehabilitative clinical outcomes, in patients treated with the pleiotropic drug cerebrolysin. J Med Life 2009;2(4):350–60. PMID: 20108748.10. Windisch M., Fruhwirth M., Grygar E., HutterPaier B. Cerebrolysin normalizes MAP2 homeostasis after glutamate induced neuronal cell death. J Neural Trans 2000;107(2):145–57.Windisch M., Fruhwirth M., Grygar E., HutterPaier B. Cerebrolysin normalizes MAP2 homeostasis after glutamate induced neuronal cell death. J Neural Trans 2000;107(2):145–57.